Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-RO6958948 Tau PET in ALFA Population
2024-516209-21-00Phase 2Authorised
- Sponsor
- Barcelonaβeta Brain Research Center
- Start
- Dec 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [18F]RO-948 in Alzheimer's disease (AD), sponsored by Barcelonaβeta Brain Research Center. Primary endpoint: Global and regional retention rate of 18F-RO6958948. Planned start Dec 2024; status: authorised.
02
Drugs
[18F]RO-948
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-516209-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516209-21-00.